about
Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysDeregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targetsCurrent Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible CrosstalkRNA-binding protein Musashi1 modulates glioma cell growth through the post-transcriptional regulation of Notch and PI3 kinase/Akt signaling pathwaysA combinatorial radiographic phenotype may stratify patient survival and be associated with invasion and proliferation characteristics in glioblastomaTranscription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targetsA single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion.Automated network analysis identifies core pathways in glioblastoma.Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation.Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas.PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry.A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiationMicroRNA-146a inhibits glioma development by targeting Notch1The challenges and the promise of molecular targeted therapy in malignant gliomas.Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells.A robust topology-based algorithm for gene expression profilingBrain tumours: classification and genesPhosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.Neurological disorders and therapeutics targeted to surmount the blood-brain barrierTargeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.Correlation study and significance of the EGFR expression in serum, lymph nodes and tumor tissue of NSCLCDeleterious c-Cbl Exon Skipping Contributes to Human Glioma.DINGO: differential network analysis in genomicsQuantitative proteomics reveals the novel co-expression signatures in early brain development for prognosis of glioblastoma multiformeRas pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.Identification of survival genes in human glioblastoma cells by small interfering RNA screening.Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).A three ion channel genes-based signature predicts prognosis of primary glioblastoma patients and reveals a chemotherapy sensitive subtype.Brain tumor stem cells as therapeutic targets in models of glioma.Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab.CREB regulates AChE-R-induced proliferation of human glioblastoma cells.Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma.Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy.Feedback circuitry between miR-218 repression and RTK activation in glioblastoma.Drug repurposing for glioblastoma based on molecular subtypes.
P2860
Q24656128-407320C3-C556-40B0-90A0-C8FCEE8C3A84Q26829873-0B477900-B9BC-458D-9357-02A27AC78083Q26865911-7813A9CE-72C5-42DE-9625-D1B29E2720EFQ28481458-4CC5259F-92F5-4E06-B35B-2DB1128B1BAFQ30177343-47FB92D3-3C1E-4730-90BD-738930AFB4F9Q30436756-6DDCF504-CD3D-4860-A9FB-DC42B9FF050FQ33212086-4D647A3D-6F65-40CA-993C-DC8CCE002AD8Q33411920-AF8762FC-EF6A-4F88-8109-64270F24310EQ33499806-82F5EF99-EB9B-45C2-AE5C-0D19ED995EFFQ33532647-FE36A582-22FD-4590-91C6-20B854C27E29Q33710967-D5D5DA21-3794-4FA6-A64F-8A199F172B52Q33809397-24CC2F6B-0663-46C0-ACA6-87ECD5F5F63CQ33880422-A7FA4C39-57AF-4662-9C5A-8968D622E5F8Q34191508-CBDCDC5B-05F5-4E09-B34C-89221FF0F7F6Q34248383-1660FFCF-E114-4DFB-91C8-FF2946B21664Q34486598-C405DD74-0E21-4A94-BBFD-90E6BBBE1374Q35092641-67C181E4-8DD9-4C14-A0F3-0054C096F07EQ35192143-7311D856-34BA-41C8-A8A9-AB4E292D23E8Q35214534-83828B72-63B1-4FEA-ACEA-C2A56F8EA761Q35214798-90C9720F-888E-4690-9668-ECFD475DAA82Q35362144-878ED128-0ED1-49DA-901C-5DA682525EFCQ35576526-BA90AA8F-FC5C-48B4-BDAF-5FE7D1C2DBF9Q35889638-85CBE24C-2F67-40DB-8384-EC32A96360E7Q36119574-8349C591-2538-4A08-B933-D2DE0E24D1C7Q36297064-1F2878E6-F4DD-4300-BAB6-530C9A44BF2CQ36439246-AED2F9B7-3562-42D5-850C-4D602FE263F9Q36480205-58E3E88E-11A7-4755-90E6-CD3FC18D8610Q36573647-2F0ACBC1-78FA-4690-AF51-D04B6E571133Q37046560-0DC04E5C-34CE-44E1-B0D3-3662EF9E1642Q37424389-9A1602D0-319C-4984-812B-0D1E56D7E28CQ37444479-FC7DB7BE-DD83-4638-90FD-C1EC759E672AQ37504538-AA5A55E6-9687-4D1A-A503-58BF7A804B6EQ37688866-3E7AE7EC-4DAA-437C-9F0C-A315F5E55FDBQ37773191-24A03189-25C2-4908-B568-A41C3B952217Q38066182-76FC3E09-2C9B-4270-86A8-AEEF88C4AF70Q38340977-611CBFF7-6605-433E-9D5F-51B60116384EQ38703888-61721E39-2AA5-4DA7-BC2A-2CDD6F6BE8D2Q38720885-573E5ACA-CCE0-4453-9946-BD11DAA3CA67Q38878830-4AC9699D-4996-45D6-B593-42475458B73DQ39327459-F5AC40BD-80A4-4364-9F0C-351AF933DC33
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Targeted molecular therapy of GBM.
@ast
Targeted molecular therapy of GBM.
@en
type
label
Targeted molecular therapy of GBM.
@ast
Targeted molecular therapy of GBM.
@en
prefLabel
Targeted molecular therapy of GBM.
@ast
Targeted molecular therapy of GBM.
@en
P1433
P1476
Targeted molecular therapy of GBM
@en
P2093
Paul S Mischel
Timothy F Cloughesy
P356
10.1111/J.1750-3639.2003.TB00006.X
P577
2003-01-01T00:00:00Z